JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 47(2013) N 1 p. 45-54;
S.S. Karshieva*, L.S. Krasikova, A.V. Belyavsky

Mesenchymal Stem Cells as Tool for Antitumor Therapy

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia

*skarshieva@gmail.com
Received - 2012-07-18; Accepted - 2012-08-22

The development of antitumor preparations with low toxicity and high selectivity of action is one of the top priorities of cancer gene therapy. Mesenchymal stem cells possess natural tropism towards tumors, a property that makes it possible to use them as vehicles for the targeted delivery of therapeutic genes to tumors of various etiologies. At present, genes that encode enzymes (cytosine deaminase, thymidine kinase, carboxyl esterase), cytokines (IL-2, IL-4, IL-12, and IFN-β), and apoptosis inducing factors (TRAIL) are used as therapeutic genes. Mesenchymal stem cells, as demonstrated using experimental models of tumors of various etiologies, as well as animals with metastases in brain and lungs, are able to successfully deliver therapeutic genes into tumors and produce a significant antitumor effect. However, to effectively use this therapeutic strategy in a clinical setting, a number of technical problems must be solved.

mesenchymal stem cells, tropism, cancer gene therapy, cancer cell therapy



JMB-FOOTER RAS-JOURNALS